Stomach Cancer Market to Record 13.9% CAGR Growth Through 2029 | Global Analysis Report

Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.

Stomach Cancer Market Outlook: How is the Market Expected to Grow by 2025?
In recent years, the market size for stomach cancer has experienced rapid expansion. Projected growth is from a valuation of $3.27 billion in 2024 to $3.74 billion in 2025, indicative of a compound annual growth rate (CAGR) of 14.1%. This growth in the historic period has been driven by factors such as the increased presence of Helicobacter pylori infection, advancements in targeted therapies, the escalating use of combined chemotherapy treatments, the improved availability of immunotherapy treatments, and significant lifestyle changes.

Stomach Cancer Market Forecast: What Size Will It Reach By 2029?
In the forthcoming years, a swift expansion is anticipated in the stomach cancer market which is projected to surge to $6.28 billion in 2029 with a compound annual growth rate (CAGR) of 13.9%. The predicted increase during this period can be credited to the escalating worldwide stomach cancer occurrence rates, intensified public and private expenditure on healthcare, the rise in approvals for targeted treatments and biologics, growing interest of pharmaceutical firms in oncology, and an increase in synergies between research institutions and biotech companies. Key trends during the forecast period will be highlighted by the incorporation of companion diagnostics, integration of genomic testing in routine clinical practice, groundbreaking combinations in immunotherapy, advancements in endoscopic techniques, and the development of therapies based on the microbiome.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/stomach-cancer-global-market-report

Which Key Market Drivers Will Shape Stomach Cancer Industry Trends in 2025-2029?
The growth of the stomach cancer market is projected to be fuelled by the increasing incidence of Helicobacter pylori infection. This infection is induced by the Helicobacter pylori bacteria, which inhabits and potentially damages the stomach lining, causing inflammation, ulcers, and boosts stomach cancer risk. The surge in the incidence of this infection is notably attributed to unsanitary conditions, giving rise to fecal-oral and oral-oral spread of the bacteria in overcrowded and dirty living environments. The primary role of Helicobacter pylori infection in promoting stomach cancer is through the creation of chronic inflammation and cellular harm in the stomach lining, triggering precancerous alterations and tumor formation. For instance, the Government of Canada reported in November 2024 that the Helicobacter pylori infection reinfection rate stood at 19% in 2023 with some variation based on geography and age brackets. Consequently, the amplifying incidence of Helicobacter pylori infection is a significant factor propelling the growth of the stomach cancer market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25913&type=smp

What Are the High-Growth Segments in the Stomach Cancer Market?
The stomach cancer market covered in this report is segmented -

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types
2) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery
3) By Route of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:
1) By Adenocarcinoma: Intestinal Type, Diffuse Type
2) By Lymphoma: Mucosa-Associated Lymphoid Tissue Lymphoma, Diffuse Large B-Cell Lymphoma
3) By Gastrointestinal Stromal Tumor: Kit-Positive Gastrointestinal Stromal Tumor, Platelet-Derived Growth Factor Receptor Alpha-mutant Gastrointestinal Stromal, Wild-Type Gastrointestinal Stromal Tumors
4) By Carcinoid Tumor: Typical Carcinoid, Atypical Carcinoid
5) By Other Types: Squamous Cell Carcinoma, Small Cell Carcinoma, Undifferentiated Tumors

Which Global Trends Are Driving Stomach Cancer Market Expansion?
Companies at the forefront of the stomach cancer treatment market are turning their focus towards the creation of innovative treatments such as claudin (CLDN18.2)-focused cytolytic antibody therapy. This breakthrough aims to augment precision in first-line treatments for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma. The therapy utilizes a monoclonal antibody engineered to specifically attach to CLDN18.2-expressing tumor cells and generate cytotoxic effects when paired with chemotherapy. This enhances both progression-free and the longevity of survival outcomes. For instance, in October 2024, Astellas Pharma US, Inc., a pharmaceutical corporation based in Japan, introduced Vyloy (zolbetuximab-clzb), a CLDN18.2-directed cytolytic antibody. It is used in the treatment of gastric and gastroesophageal junction (GEJ) cancers and is an advanced biologic therapy given intravenously with fluoropyrimidine- and platinum-based chemotherapy. It resulted in a median progression-free survival advantage of 10.6 months and an overall survival of 18.2 months in clinical trials. This therapy targets CLDN18.2-positive cancer cells specifically, minimizing off-target toxicity while maximizing treatment specificity. This marks a considerable evolution in personalized cancer treatment for advanced gastric cancer.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25913&type=smp

Who Are the Fastest-Growing Companies in the Stomach Cancer Industry?
Major companies operating in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis Ag, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited., Eli Lilly And Company, Amgen Inc, Mayo Clinic, Daiichi Sankyo Company Limited., Illumina Inc., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited., Guardant Health Inc., Zai Lab Limited., MacroGenics Inc.

What Is the Regional Outlook for the Stomach Cancer Market by 2029?
North America was the largest region in the stomach cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stomach cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.